drugset / Trial / NCT07388602
A Study to Evaluate the Safety and Efficacy of SCTC21C in Combination With Bortezomib, Cyclophosphamide, and Dexamethasone in Patients With Newly Diagnosed Systemic Light-Chain Amyloidosis (NDSLCA)
RandomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to evaluate the efficacy and safety of SCTC21C plus cyclophosphamide, bortezomib and dexamethasone (VCd) compared with VCd alone in treatment of newly diagnosed amyloid light chain (AL) amyloidosis participants.
Timeline
- Start
- 2026-01-08
- Primary completion
- 2027-12
- Completion
- 2028-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | SCTC21C | Unknown | — | Subcutaneous |
| Background | Bortezomib | Small molecule | — | Subcutaneous |
| Background | Cyclophosphamide | Other / unclassified | — | Oral |
| Background | Dexamethasone | Small molecule | — | Oral |